Gene editing has already crossed its most important threshold: it is no longer just an experimental technology. The first commercial product is generating revenue, its eligible market just expanded, and several new programs are moving through the clinic.
The stock remains risky and deeply out of favor, but that combination is exactly what makes the current setup interesting.
Official Support Emerges (Sponsored)
Elon Musk has quietly launched a new venture outside rockets, EVs, Neuralink, and tunnels.
Trump is pushing emergency support to roll out the tech fast. It is already live in multiple states.
Demand is surging too. The Financial Times says Sam Altman is calling people to build it for OpenAI.
The key is that a few little-known companies control the supply chain.
You can buy their stocks now through a regular brokerage account before the story goes mainstream.
Click here to see how you could back Musk’s next venture today.
*This ad is sent on behalf of Altimetry, 110 Cambridge Street, Cambridge, MA 02141. If you would like to optout from receiving offers from Altimetry please click here.
What Just Happened
The first approved therapy reached younger patients
CRISPR Therapeutics AG (NASDAQ: CRSP) and its partner Vertex Pharmaceuticals recently received FDA approval to expand CASGEVY to patients ages two and older with severe sickle cell disease or transfusion-dependent beta thalassemia.
The previous U.S. approval covered patients ages 12 and older. The expanded label adds approximately 5,500 eligible children in the U.S. and makes CASGEVY the first approved genetic therapy available to children as young as two across both diseases.
That is a meaningful commercial catalyst. Treating patients earlier can prevent years of disease-related damage while enlarging the addressable market for a therapy already generating revenue.
The stock remains near its lows
CRSP recently traded around $47.64, down roughly 19% over the past year and close to its 52-week low of $44.12.
Investors remain frustrated by the slow CASGEVY rollout, continuing operating losses, and the long timelines attached to clinical-stage biotech.
The shares are also down sharply from their recent highs despite the company now having something most gene-editing competitors do not: an approved product.
That disconnect creates the opportunity. The market is valuing CRSP mainly as an unprofitable pipeline company even though its technology has already produced a commercial medicine.
CASGEVY Is Building Momentum
Revenue is finally becoming visible
CASGEVY generated $43 million in first-quarter revenue. More than 500 patients globally had initiated the treatment journey by early May, up from 147 patients who underwent their first cell collection during 2025.
The rollout is still early, but the direction is clear. Treatment centers are gaining experience, reimbursement agreements are expanding, and more eligible patients are entering the process.
CRISPR Therapeutics receives 40% of the program’s net profits and losses, while Vertex receives 60% and leads commercialization.
That structure gives CRSP access to Vertex’s global regulatory, reimbursement, manufacturing, and commercial capabilities. The trade-off is that CRSP receives only part of the economics and shares the substantial costs of launching a complex therapy.
The treatment process remains the bottleneck
CASGEVY is not a normal prescription. Doctors collect a patient’s blood stem cells, edit them outside the body, prepare the patient with chemotherapy, and then reinfuse the modified cells.
The process can take months. Revenue is generally recognized only after the treatment is completed, meaning patient initiations do not immediately appear as sales.
That explains why commercial progress can look slow even while the patient pipeline is expanding. The launch depends on specialized treatment centers, payer approvals, manufacturing coordination, and patients willing to undergo an intensive procedure.
The expanded pediatric approval makes the opportunity larger, but it does not make the process simpler.
Poll: What's your biggest edge over professional institutional investors?
America’s AI Buildout (Sponsored)
Taiwan Semiconductor just posted strong earnings and raised its full-year growth outlook above 40%.
But the bigger story may be its expanding U.S. investment. The chipmaker is reportedly adding another $100 billion to the $165 billion it already committed to American manufacturing.
That is $265 billion moving into U.S. chip infrastructure as the AI race accelerates.
One analyst believes this spending points to a much larger government-backed AI project now taking shape, and he has identified one little-known company that could be positioned directly in its path.
See the company positioned for America’s next AI buildout.
The Pipeline Is The Bigger Prize
Cardiovascular editing could reach a much broader market
The most important pipeline asset may be CTX310, an in vivo therapy targeting ANGPTL3. Unlike CASGEVY, which edits cells outside the body, CTX310 is delivered through an intravenous infusion designed to edit genes directly inside the liver.
Early Phase 1 results showed deep and durable reductions in triglycerides and LDL cholesterol after a single treatment. The company has advanced the program into Phase 1b studies focused on severe hypertriglyceridemia and refractory high cholesterol.
This is potentially a much larger commercial market than rare blood disorders.
Cardiovascular disease affects millions of patients, and a one-time treatment that produces lasting cholesterol reductions could challenge medicines that require repeated injections or daily pills.
The company expects to provide another CTX310 update during the second half of 2026.
More liver-directed programs are advancing
CRSP is using the same lipid nanoparticle delivery platform across several additional programs.
CTX321 targets elevated lipoprotein(a), an inherited cardiovascular risk factor that cannot be controlled effectively through diet or conventional cholesterol drugs. An earlier version of the program produced reductions of up to 73%, while CTX321 uses a more potent guide RNA.
CTX460 targets alpha-1 antitrypsin deficiency, a genetic disease that can damage the lungs and liver. CTX340 targets angiotensinogen for difficult-to-control hypertension.
The company is also developing CTX611, a long-acting RNA interference therapy aimed at Factor XI, with a clinical update expected in the second half.
Not every program will succeed. But the platform approach means one validated delivery system can support multiple shots on goal across cardiovascular, liver, autoimmune, and genetic diseases.
Elite Trade Club Insider
A $33 Million Insider Cluster Just Hit Two Near-High Market Leaders
You’re watching one financial winner benefit from stronger trading and balance-sheet growth, while one AI giant keeps posting explosive cloud numbers. Elite Trade Club Insider readers are seeing what the raw feeds miss: the larger sale cluster was driven by deeply profitable option exercises, while duplicated venture-fund entries were not actually multimillion-dollar sales of the tech giant’s stock.
You’re reading the free version. Here’s what we held back.
Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.
A subscription gets you:
The insider buys, options bets, and dark pool moves the free edition can't show you. Unlocked every weekday.
A Sunday Deep Dive that tells you where to look before Monday's bell rings.
The Friday Smart Money Brief: who bought, who sold, where the big options bets landed, and where institutions are hiding volume. Three data layers. One email.
A Monthly Insider Scorecard so you always know whether smart money is buying or selling the market.
Every past Insider edition, unlocked, on elitetrade.club. Go back and see what you missed.
$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.
The Balance Sheet Provides Time
Cash exceeds half the market value
CRISPR Therapeutics ended Q1 with approximately $2.44 billion in cash, cash equivalents, and marketable securities. That compares with a market capitalization of roughly $4.6 billion based on the price data you shared.
The company posted a first-quarter net loss of $122.9 million, improving from a $136 million loss a year earlier. Research and development spending declined slightly to $68.6 million.
At the current loss rate, the cash balance provides a substantial development runway. CRSP does not need to raise equity immediately to keep its major clinical programs moving.
The new notes create dilution risk
The cash balance increased partly because the company issued $600 million of convertible senior notes due in 2031, generating approximately $585 million in net proceeds.
Convertible debt is less immediately dilutive than issuing common shares, but it can eventually increase the share count if the notes convert. The company also retains access to an at-the-market equity program.
That means dilution remains a real long-term risk. The balance sheet is strong, but it was not built entirely from product profits.
Market Crash Defense (Sponsored)
Ray Dalio and major Wall Street banks are warning that stocks could face one of the toughest stretches in decades.
One financial tech team says it has built a free tool designed to help investors spot trade ideas and protect their portfolio without options, crypto, gold, or penny stocks.
More than 2,000 early adopters are already using it.
Try the free market-defense tool here.
*This ad is sent on behalf of TradeSmith at 1125 N. Charles Street, Baltimore, Maryland 21201. If you’re not interested in this opportunity, please click here.
Why The Stock Has A Case
The approved product validates the science
Many gene-editing companies are still trying to prove their technology can produce an approved medicine. CRISPR Therapeutics has already done it.
CASGEVY validates the company’s core editing platform and gives regulators, physicians, and patients real-world experience with a CRISPR-based therapy.
The current market value also gives investors exposure to the entire pipeline without assigning much value to several early-stage programs. If CTX310 or another in vivo candidate produces convincing clinical results, the stock can rerate quickly.
Short interest can amplify a catalyst
CRSP remains one of the more heavily shorted mid-cap biotechnology stocks. That reflects legitimate skepticism around commercialization, losses, and pipeline risk.
It also means a strong clinical update, faster CASGEVY uptake, or strategic partnership could trigger a sharper move as bearish investors cover positions.
Short interest is not an investment thesis by itself, but it can magnify the reaction when fundamentals improve.
What Could Trip It Up
Clinical success is never guaranteed
Encouraging early data does not guarantee approval. Later trials can reveal weaker efficacy, safety concerns, or manufacturing challenges.
CASGEVY may remain slow to scale
The treatment is expensive, operationally complex, and demanding for patients. Commercial growth may take longer than investors expect even with broader reimbursement and eligibility.
Losses and dilution will continue
CRSP expects to remain unprofitable for several years. Pipeline expansion, manufacturing, and clinical trials require sustained spending.
My Take
Speculative buy at current levels. CRISPR Therapeutics has an approved therapy, growing commercial uptake, a newly expanded pediatric market, more than $2.4 billion in liquidity, and several potentially valuable in vivo programs.
The stock’s decline has created an attractive entry for investors who understand that clinical milestones—not quarterly earnings—will drive returns.
The key risk is that commercialization and clinical progress remain slower than expected. CASGEVY is difficult to deliver, the pipeline is unproven beyond early trials, and future dilution remains possible.
This belongs in the higher-risk portion of a portfolio, not alongside established profitable healthcare holdings.
Action Recap
🧬 Looking to buy? Start with a small speculative position near current levels and leave room to add after stronger clinical data.
📈 Already own it? Keep holding while CASGEVY initiations rise and CTX310 advances through Phase 1b.
⚠️ Main risk to respect: A disappointing clinical update can erase years of expected pipeline value in one session.
You Read This Far. Here's Where the Real Work Lives.
We run three live portfolios on Autopilot, and everything about them is public: every position, every allocation, every trade, visible the moment it happens.
We keep our own money in each one, because analysis you won't fund yourself is just content.
THE UNBREAKABLE STACK
Our growth book: durable software and cybersecurity names built to compound quietly for years.
THE HORMUZ PREMIUM
Our energy thesis: built for how that sector actually pays, over quarters, not headlines.
THE SQUEEZE
The defensive sleeve: staples and steady compounders, boring on purpose, built for the nights you'd rather sleep than watch futures.
And here's the part that makes it effortless: Autopilot does the trading for you. Connect the brokerage you already use (Robinhood, Schwab, Fidelity, and more) and every move we make gets mirrored in your own account automatically.
Your money never leaves your brokerage. It stays in your account, under your control, and you can override any trade or disconnect anytime. Autopilot even rebalances automatically when allocations drift, and you get a notification every time something happens.
No watching tickers. No timing entries. No fat-finger mistakes at market open. You pick the portfolio, we do the work, your account follows along.
Pick the one that fits your risk level, or run all three:
Live portfolios, real positions, our own capital at stake. Your funds stay in your own brokerage account. Past performance doesn't guarantee future results.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
